Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial

Besse, B.Garcia Campelo, M. R.Cobo Dols, M. A.Quoix, E.Madroszyk, A.Felip, E.Cappuzzo, F.Denis, F.Hilgers, W.Romano, G.Debieuvre, D.Baldini, E.Galetta, D.Viteri, S.Phan, M.Schuette, W.Zer, A.Costantini, D.Dziadziuszko, R.Giaccone, G.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/26997enActivity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trialconference outputopen access10.1016/j.annonc.2021.08.21261569-8041https://doi.org/10.1016/j.annonc.2021.08.2126700527704005